These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8794165)

  • 1. Engineering and design of blood substitutes.
    Sanders KE; Ackers G; Sligar S
    Curr Opin Struct Biol; 1996 Aug; 6(4):534-40. PubMed ID: 8794165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-generation blood substitutes: what have we learned? Biochemical and physiological perspectives.
    Alayash AI; D'Agnillo F; Buehler PW
    Expert Opin Biol Ther; 2007 May; 7(5):665-75. PubMed ID: 17477804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Site-specific modifications and toxicity of blood substitutes. The case of diaspirin cross-linked hemoglobin.
    D'Agnillo F; Alayash AI
    Adv Drug Deliv Rev; 2000 Feb; 40(3):199-212. PubMed ID: 10837790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to evaluate blood substitutes for endothelial cell toxicity.
    Gaucher C; Menu P
    Antioxid Redox Signal; 2008 Jul; 10(7):1153-62. PubMed ID: 18331203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood substitutes based on modified hemoglobin.
    Bakker JC; Bleeker WK
    Vox Sang; 1994; 67 Suppl 3():139-42. PubMed ID: 7975479
    [No Abstract]   [Full Text] [Related]  

  • 6. A new polyethyleneglycol-derivatized hemoglobin derivative with decreased oxygen affinity and limited toxicity.
    Zolog O; Mot A; Deac F; Roman A; Fischer-Fodor E; Silaghi-Dumitrescu R
    Protein J; 2011 Jan; 30(1):27-31. PubMed ID: 21161348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of recombinant octameric hemoglobin with endothelial cells.
    Gaucher C; Domingues-Hamdi É; Prin-Mathieu C; Menu P; Baudin-Creuza V
    C R Biol; 2015 Feb; 338(2):95-102. PubMed ID: 25543885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peritoneal accumulation of infused stroma-free hemoglobin. Potential toxicity of an oxygen-carrying substitute.
    Velky TS; Lee ES; Maffuid PW; Robinson GT; Yang JC; Greenburg AG
    Arch Surg; 1987 Mar; 122(3):355-7. PubMed ID: 3827578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Present status of modified hemoglobin as blood substitutes and oral therapy for end stage renal failure using artificial cells containing genetically engineered cells.
    Chang TM
    Ann N Y Acad Sci; 2001 Nov; 944():362-72. PubMed ID: 11797686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxygen therapeutics: can we tame haemoglobin?
    Alayash AI
    Nat Rev Drug Discov; 2004 Feb; 3(2):152-9. PubMed ID: 15043006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Red cell substitutes.
    Winslow RM
    Semin Hematol; 2007 Jan; 44(1):51-9. PubMed ID: 17198847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemoglobin and free radicals: implications for the development of a safe blood substitute.
    Alayash AI; Cashon RE
    Mol Med Today; 1995 Jun; 1(3):122-7. PubMed ID: 9415147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood substitutes: engineering the haemoglobin molecule.
    Vandegriff KD
    Biotechnol Genet Eng Rev; 1992; 10():403-53. PubMed ID: 1301743
    [No Abstract]   [Full Text] [Related]  

  • 14. Artificial oxygen carriers: scientific and biotechnological points of view.
    Simoni J
    Artif Organs; 2009 Feb; 33(2):92-6. PubMed ID: 19178451
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety evaluation of hemoglobin solutions.
    Fratantoni JC
    Prog Clin Biol Res; 1983; 122():111-5. PubMed ID: 6878352
    [No Abstract]   [Full Text] [Related]  

  • 16. Basic science offers a challenge for developing hemoglobin based oxygen carriers into therapeutic agents.
    Bucci E
    Artif Cells Blood Substit Immobil Biotechnol; 2011 Aug; 39(4):206-13. PubMed ID: 21692690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development and challenge of modified hemoglobins as red blood cell substitutes].
    Lu XL
    Sheng Wu Gong Cheng Xue Bao; 2006 Jan; 22(1):7-18. PubMed ID: 16572834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety studies of modified hemoglobin as an oxygen-carrying blood substitute.
    Chang TM
    Hematol Pathol; 1993; 7(1):49-55. PubMed ID: 8468266
    [No Abstract]   [Full Text] [Related]  

  • 19. [Comparative study of chemically modified hemoglobins as a basis for oxygen-carrying blood substitutes].
    Azhigirova MA; Viazova EP; Shuvalova AL; Vashkevich MG
    Biull Eksp Biol Med; 1993 Apr; 115(4):364-6. PubMed ID: 8049393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risks of blood transfusions and the shortage of supply leads to the quest for blood substitutes.
    Nouwairi NS
    AANA J; 2004 Oct; 72(5):359-64. PubMed ID: 15529732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.